FDA Clears Automated Dosimetry with the Monte Carlo Method for Radionuclide Therapy
The clearance may facilitate improved standardization and efficiency of dosimetry-guided, theranostic applications of radiopharmaceutical therapy.
While calculations with previous use of Monte Carlo dosimetry could take hours, the Food and Drug Administration (FDA) has granted 510(k) clearance for a dose planning method that facilitates automated use of this dosimetry technique in seconds for radiotherapy applications.
Clinicians will now be able to access automated Monte Carlo dosimetry with the dose planning method through the MIM SurePlan MRT platform (MIM Software/GE HealthCare). While GE HealthCare said the Monte Carlo method has been acknowledged as a gold standard in dosimetry for radiophamaceutical therapy, clinicians can now review absorbed doses with this technique in a few clicks.
The availability of a dose planning method through the MIM SurePlan MRT platform may allow clinicians access to automated dosimetry assessment with the Monte Carlo method in seconds, according to GE HealthCare, the manufacturer of the MIM SurePlan MRT platform. (Photo courtesy of GE HealthCare.)
“It is exciting that the dose planning method code developed and validated at our institution will be available to the theranostics community at large with the recent FDA clearance,” said Yuni Dewaraja, PhD, a professor of radiology at the University of Michigan. “This opens up the possibility for harmonized and accurate patient-specific dosimetry across centers, which can lead to robust dose-effect relationships, dosimetry-guided radiopharmaceutical therapy, and ultimately a greater benefit for patients receiving these promising therapies.”
GE HealthCare added that the MIM SurePlan MRT automates dosimetry processes such as organ-at-risk segmentation, time-activity curve fitting and single photon emission computed tomography (SPECT) reconstruction.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
